Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2018 | Lung cancer immuno-oncology clinical trial combinations: inhibiting IDO

There are numerous ongoing and planned clinical trials investigating immuno-oncology (IO) agents for lung cancer, particularly in combination with other classes of therapy moving forwards. Here, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the key combinations being investigated. Dr Greystoke highlights investigations combining checkpoint inhibitors with an inhibitor of IDO, which may be involved in IO resistance. He also covers the challenges being faced in developing these combination regimens, highlighting the struggle with prioritization and toxicity. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.